SSY Group's (HKG:2005) SYN045 tablets, a PGI2 receptor agonist, obtained approval from China's National Medical Products Administration for adding three different specifications for a phase I clinical trial, a Thursday Hong Kong bourse filing said.
The indications will help meet the diversified needs of clinical trials, achieve dose gradient for patients of different age groups, further optimize precise dosing regimen, and boost the clinical application value of the tablets.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.